Evaluating kidney damage from immunotherapy in cancer patients
Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer
This study is testing whether a kidney biopsy can help doctors understand and manage kidney damage in cancer patients who are receiving immunotherapy and experiencing kidney problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Vandoeuvre les nancy) |
| Trial ID | NCT06357871 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the role of renal biopsy in patients with solid cancers who are treated with checkpoint inhibitors and experience acute renal failure. The goal is to establish a probability score for identifying histological lesions associated with nephrotoxicity, which can help guide nephrologists and oncologists in managing acute kidney injury (AKI) related to immunotherapy. By assessing the necessity of renal biopsy, the study aims to minimize unnecessary risks associated with the procedure while optimizing patient care.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with solid cancers treated by checkpoint inhibitors who have experienced renal failure.
Not a fit: Patients who do not have renal failure or are not receiving immunotherapy are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management of kidney-related side effects in cancer patients receiving immunotherapy.
How similar studies have performed: While the approach of assessing nephrotoxicity in immunotherapy is gaining attention, this specific methodology of using renal biopsy probability scores is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over 18 years old Diagnosis of solid cancer treated by immunotherapy such as checkpoint inhibitor, associated or not with chemotherapy Renal failure having benefited from a renal biopsy Exclusion Criteria: * None
Where this trial is running
Vandoeuvre les nancy
- CHRU de Nancy — Vandoeuvre les nancy, France (Recruiting)
Study contacts
- Principal investigator: Adrien Flahault, MD, PhD — CHRU de Nancy
- Study coordinator: Adrien Flahault, MD, PhD
- Email: a.flahault@chru-nancy.fr
- Phone: +33 3 83 15 31 69
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.